Advertisement


Michael Soike, MD, on Brain Metastases: Radiosurgery vs Radiotherapy

2018 ASTRO Annual Meeting

Advertisement

Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival compared with whole-brain radiotherapy for patients with progressive brain metastases (Presentation 296 in Scientific Symposium 40).



Related Videos

Head and Neck Cancer

Bhisham Chera, MD, on Oropharyngeal Cancer: Expert Perspective on Surveillance

Bhisham Chera, MD, of the University of North Carolina, discusses using human papillomavirus found in plasma circulating tumor DNA to monitor cancer recurrence in HPV-associated oropharyngeal cancer (Abstract LBA6).

 

Prostate Cancer

Howard M. Sandler, MD, on Localized Prostate Cancer: Radiation Therapy Guidelines

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, summarizes a session he moderated that included discussion of an ASTRO, ASCO, and AUA guideline; indications and dose fractionation; treatment volumes; and the use of IGRT and IMRT (Panel 03).

Solid Tumors

David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial

David Palma, MD, PhD, of the London Health Sciences Centre, discusses study findings on improvement in survival following stereotactic ablative radiation for oligometastatic tumors (Presentation 5 in PL 01).

Head and Neck Cancer
Symptom Management

Thomas Galloway, MD, on Oropharyngeal Cancer: Improving Outcomes and Reducing Toxicity

Thomas Galloway, MD, of Fox Chase Cancer Center, summarizes a session on head and neck cancer that included findings on reducing oral mucositis, improving quality of life with deintensified chemoradiotherapy, and the costs of dose de-escalation (Scientific Session 31).

Lung Cancer

Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial

Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall survival compared with maintenance therapy and observation in oligometastatic non–small cell lung cancer (Abstract LBA3).

Advertisement

Advertisement




Advertisement